Genomic Health Inc. (GHDX) 26.59 $GHDX
Genomic Health Brings Liquid Biopsy Test for Stage IV Cancer
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 7:13AM CDT
Genomic's (GHDX) Oncotype SEQ facilitates personalized treatment of patients suffering from stage four solid tumor cancer.
BAX: 45.96 (+1.02), LMAT: 14.82 (+0.13), ILMN: 146.59 (+5.70), GHDX: 26.59 (+0.11)
Nature Partner Journals Publish Five-year Outcomes Results from SEER Registry Demonstrating Oncotype DX® Accurately Identifies Early-stage Breast Cancer Patients with Excellent Survival
PR Newswire - Wed Jun 08, 3:05PM CDT
Genomic Health, Inc. (Nasdaq: GHDX) today announced the publication of results from the National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results (SEER) Registry in Nature Partner Journals Breast Cancer, a peer-reviewed journal published by Nature. Published results demonstrated, based on evidence from over 44,600 breast cancer patients, that the Oncotype DX® Breast Recurrence Score(TM) accurately predicts survival outcomes in patients with node-negative and node-positive disease in contemporary "real-world" clinical practice.
GHDX: 26.59 (+0.11)
Oncotype DX® presentations at 2016 ASCO® annual meeting reinforce Genomic Health's leadership in optimising breast cancer treatment
PR Newswire Europe - Mon Jun 06, 2:00AM CDT
Recent publication in Journal of Clinical Oncology demonstrates that Oncotype DX predicts late distant recurrence in breast cancer
GHDX: 26.59 (+0.11)
Genomic Health Announces Multiple Oncotype DX® Presentations at ASCO 2016 Showcasing Industry-leading Commitment to Bringing Precision Medicine to Cancer Patients
PR Newswire - Sun Jun 05, 7:00AM CDT
Genomic Health, Inc. (Nasdaq: GHDX) today announced results from seven Oncotype DX® studies being presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting. Results include four new analyses from the National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results (SEER) Registry with more than 44,600 breast cancer patients. The SEER analyses reconfirmed through prospective outcomes data that the Oncotype DX® Breast Recurrence Score(TM) is an accurate predictor of five-year survival in patients with node-positive and node-negative disease in contemporary "real-world" clinical practice and revealed disparities in Oncotype DX testing use and patient outcomes.
GHDX: 26.59 (+0.11)
Genomic Health to Present at Jefferies 2016 Healthcare Conference
PR Newswire - Tue May 31, 7:00AM CDT
Genomic Health, Inc. (Nasdaq: GHDX) today announced that Brad Cole, Chief Operating Officer and Chief Financial Officer, will present at the Jefferies 2016 Healthcare Conference at the Grand Hyatt in New York City on Tuesday, June 7, 2016 at 8:30 a.m. Eastern Time.
GHDX: 26.59 (+0.11)
Genomic Health Announces Presentation of Seven Oncotype DX® Studies at the 2016 American Society of Clinical Oncology Annual Meeting, Including Additional Prospective Outcomes Analysis
PR Newswire - Thu May 26, 7:00AM CDT
Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from seven Oncotype DX® studies at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, which will take place June 3-7 at McCormick Place in Chicago. The results will include:
GHDX: 26.59 (+0.11)
Genomic Health Announces Publication in Journal of Clinical Oncology Demonstrating Oncotype DX® Predicts Late Distant Recurrence in Breast Cancer
PR Newswire - Wed May 25, 7:00AM CDT
Genomic Health, Inc. (Nasdaq: GHDX) today announced that the Journal of Clinical Oncology, the official journal of the American Society of Clinical Oncology (ASCO), published results from a large study confirming the ability of the Oncotype DX® Breast Recurrence Score(TM), in combination with quantitative estrogen-receptor (ER) expression, to accurately predict after five years of tamoxifen therapy the risk of late distant recurrence up to 15 years in patients with early-stage, hormone receptor-positive breast cancer. These findings suggest that Oncotype DX may help identify which patients are most likely to benefit from extended hormonal treatment with tamoxifen.
GHDX: 26.59 (+0.11)
Genomic Health (GHDX): Q1 Results Strong, Costs Escalate
Zacks Equity Research - Zacks Investment Research - Tue May 24, 7:25AM CDT
Genomic Health (GHDX) has had a satisfactory run so far this year with its first-quarter earnings improving year over year and the top line surpassing the Zacks Consensus Estimate.
BSX: 22.97 (+0.31), BAX: 45.96 (+1.02), LMAT: 14.82 (+0.13), GHDX: 26.59 (+0.11)
Correction: Earns-Genomic Health story
AP - Thu May 05, 12:41PM CDT
REDWOOD CITY, Calif. (AP) — In a story about Genomic Health's quarterly earnings — generated by Automated Insights using data from Zacks Investment Research — The Associated Press reported erroneously that the company missed expectations. Revised estimates from Zack's show that analysts' consensus expectation was for a loss of 23 cents a share, which the company matched.
GHDX: 26.59 (+0.11)
Why Genomic Health, Inc. Earned a Higher Share Price
Brian Orelli, The Motley Fool - Motley Fool - Thu May 05, 11:49AM CDT
What: Genomic Health is up 11% at 12 p.m. ET after reporting solid earnings following the bell yesterday. So what: Revenue increased 19% year over year while tests delivered increased 16%. Revenue is growing faster than test volume because...
GHDX: 26.59 (+0.11)
Genomic Health (GHDX): Q1 Loss Narrows Y/Y, Margins Weak
Zacks Equity Research - Zacks Investment Research - Thu May 05, 8:03AM CDT
Genomic Health (GHDX) started 2016 on a satisfactory note.
BSX: 22.97 (+0.31), SRDX: 24.06 (+0.71), BAX: 45.96 (+1.02), GHDX: 26.59 (+0.11)
Genomic Health Reports Double-Digit Revenue and Test Growth in Announcement of First Quarter 2016 Financial Results
PR Newswire - Wed May 04, 3:05PM CDT
Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended March 31, 2016.
GHDX: 26.59 (+0.11)
Genomic Health to Present at Bank of America Merrill Lynch 2016 Health Care Conference
PR Newswire - Tue May 03, 3:05PM CDT
Genomic Health, Inc. (Nasdaq: GHDX) today announced that Kim Popovits, Chairman of the Board, Chief Executive Officer and President, will present at the Bank of America Merrill Lynch 2016 Health Care Conference at the Encore at Wynn Las Vegas on Tuesday, May 10, 2016 at 3:40 p.m. Pacific Time.
GHDX: 26.59 (+0.11)
3 Things to Watch as Genomic Health, Inc. Releases Earnings
Brian Orelli, The Motley Fool - Motley Fool - Tue May 03, 2:55PM CDT
As Genomic Health prepares to release earnings on Wednesday after the closing bell, here are three things investors should be watching from the cancer-test maker. 1. Tests performed Revenue is important, but with not all of its tests being...
MYGN: 30.76 (-0.21), GHDX: 26.59 (+0.11)
Genomic Health to Announce First Quarter 2016 Financial Results and Host Conference Call on Wednesday, May 4, 2016
PR Newswire - Wed Apr 27, 7:00AM CDT
Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Wednesday, May 4 at 4:30 p.m. Eastern Time to discuss its first quarter 2016 financial results. The call and webcast will follow the release of the first quarter financial results after market close.
GHDX: 26.59 (+0.11)
How Risky Is Myriad Genetics Stock?
Keith Speights, The Motley Fool - Motley Fool - Tue Apr 12, 7:22AM CDT
Image source: Myriad Genetics. April showers bring myriad flowers. That's not really how the old adage goes, but the changed wording just might be applicable to Myriad Genetics . Shares of the molecular diagnostics testing company took a...
MYGN: 30.76 (-0.21), FMI: 19.43 (+0.01), ILMN: 146.59 (+5.70), GHDX: 26.59 (+0.11)
Genomic Health (GHDX): Moving Average Crossover Alert
Zacks Equity Research - Zacks Investment Research - Fri Apr 01, 5:35AM CDT
Genomic Health Inc. (GHDX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
GHDX: 26.59 (+0.11)
Shares of GHDX Down 22.4% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Mar 24, 1:02PM CDT
SmarTrend identified a Downtrend for Genomic Health (NASDAQ:GHDX) on January 11th, 2016 at $29.54. In approximately 2 months, Genomic Health has returned 22.41% as of today's recent price of $22.92.
GHDX: 26.59 (+0.11)
Genomic Health: Bleak Q4 on Lower Margins, Higher Costs
Zacks Equity Research - Zacks Investment Research - Fri Mar 18, 2:00PM CDT
Genomic Health's (GHDX) fourth-quarter 2015 adjusted loss came in wider than expected, while the top line closely missed the Zacks Consensus Estimate
OFIX: 44.22 (-0.11), GHDX: 26.59 (+0.11), HRC: 52.06 (+0.78), OSUR: 6.81 (+0.04)
Genomic's Oncotype DX Positive in 5-Year Breast Cancer Trial
Zacks Equity Research - Zacks Investment Research - Tue Mar 15, 1:10PM CDT
We believe these 5-year favorable results from the PlanB study will enhance Genomic Health's (GHDX) competitive leverage in the billion dollar global market for breast cancer diagnostics and drug technologies.
OFIX: 44.22 (-0.11), GHDX: 26.59 (+0.11), HRC: 52.06 (+0.78), OSUR: 6.81 (+0.04)
Genomic Health Brings Liquid Biopsy Test for Stage IV Cancer
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 7:13AM CDT
Genomic's (GHDX) Oncotype SEQ facilitates personalized treatment of patients suffering from stage four solid tumor cancer.
BAX: 45.96 (+1.02), LMAT: 14.82 (+0.13), ILMN: 146.59 (+5.70), GHDX: 26.59 (+0.11)
Nature Partner Journals Publish Five-year Outcomes Results from SEER Registry Demonstrating Oncotype DX® Accurately Identifies Early-stage Breast Cancer Patients with Excellent Survival
PR Newswire - Wed Jun 08, 3:05PM CDT
Genomic Health, Inc. (Nasdaq: GHDX) today announced the publication of results from the National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results (SEER) Registry in Nature Partner Journals Breast Cancer, a peer-reviewed journal published by Nature. Published results demonstrated, based on evidence from over 44,600 breast cancer patients, that the Oncotype DX® Breast Recurrence Score(TM) accurately predicts survival outcomes in patients with node-negative and node-positive disease in contemporary "real-world" clinical practice.
GHDX: 26.59 (+0.11)
Oncotype DX® presentations at 2016 ASCO® annual meeting reinforce Genomic Health's leadership in optimising breast cancer treatment
PR Newswire Europe - Mon Jun 06, 2:00AM CDT
Recent publication in Journal of Clinical Oncology demonstrates that Oncotype DX predicts late distant recurrence in breast cancer
GHDX: 26.59 (+0.11)
Genomic Health Announces Multiple Oncotype DX® Presentations at ASCO 2016 Showcasing Industry-leading Commitment to Bringing Precision Medicine to Cancer Patients
PR Newswire - Sun Jun 05, 7:00AM CDT
Genomic Health, Inc. (Nasdaq: GHDX) today announced results from seven Oncotype DX® studies being presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting. Results include four new analyses from the National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results (SEER) Registry with more than 44,600 breast cancer patients. The SEER analyses reconfirmed through prospective outcomes data that the Oncotype DX® Breast Recurrence Score(TM) is an accurate predictor of five-year survival in patients with node-positive and node-negative disease in contemporary "real-world" clinical practice and revealed disparities in Oncotype DX testing use and patient outcomes.
GHDX: 26.59 (+0.11)
Genomic Health to Present at Jefferies 2016 Healthcare Conference
PR Newswire - Tue May 31, 7:00AM CDT
Genomic Health, Inc. (Nasdaq: GHDX) today announced that Brad Cole, Chief Operating Officer and Chief Financial Officer, will present at the Jefferies 2016 Healthcare Conference at the Grand Hyatt in New York City on Tuesday, June 7, 2016 at 8:30 a.m. Eastern Time.
GHDX: 26.59 (+0.11)
Genomic Health Announces Presentation of Seven Oncotype DX® Studies at the 2016 American Society of Clinical Oncology Annual Meeting, Including Additional Prospective Outcomes Analysis
PR Newswire - Thu May 26, 7:00AM CDT
Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from seven Oncotype DX® studies at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, which will take place June 3-7 at McCormick Place in Chicago. The results will include:
GHDX: 26.59 (+0.11)
Genomic Health Announces Publication in Journal of Clinical Oncology Demonstrating Oncotype DX® Predicts Late Distant Recurrence in Breast Cancer
PR Newswire - Wed May 25, 7:00AM CDT
Genomic Health, Inc. (Nasdaq: GHDX) today announced that the Journal of Clinical Oncology, the official journal of the American Society of Clinical Oncology (ASCO), published results from a large study confirming the ability of the Oncotype DX® Breast Recurrence Score(TM), in combination with quantitative estrogen-receptor (ER) expression, to accurately predict after five years of tamoxifen therapy the risk of late distant recurrence up to 15 years in patients with early-stage, hormone receptor-positive breast cancer. These findings suggest that Oncotype DX may help identify which patients are most likely to benefit from extended hormonal treatment with tamoxifen.
GHDX: 26.59 (+0.11)
Genomic Health (GHDX): Q1 Results Strong, Costs Escalate
Zacks Equity Research - Zacks Investment Research - Tue May 24, 7:25AM CDT
Genomic Health (GHDX) has had a satisfactory run so far this year with its first-quarter earnings improving year over year and the top line surpassing the Zacks Consensus Estimate.
BSX: 22.97 (+0.31), BAX: 45.96 (+1.02), LMAT: 14.82 (+0.13), GHDX: 26.59 (+0.11)
Correction: Earns-Genomic Health story
AP - Thu May 05, 12:41PM CDT
REDWOOD CITY, Calif. (AP) — In a story about Genomic Health's quarterly earnings — generated by Automated Insights using data from Zacks Investment Research — The Associated Press reported erroneously that the company missed expectations. Revised estimates from Zack's show that analysts' consensus expectation was for a loss of 23 cents a share, which the company matched.
GHDX: 26.59 (+0.11)
Why Genomic Health, Inc. Earned a Higher Share Price
Brian Orelli, The Motley Fool - Motley Fool - Thu May 05, 11:49AM CDT
What: Genomic Health is up 11% at 12 p.m. ET after reporting solid earnings following the bell yesterday. So what: Revenue increased 19% year over year while tests delivered increased 16%. Revenue is growing faster than test volume because...
GHDX: 26.59 (+0.11)
Genomic Health (GHDX): Q1 Loss Narrows Y/Y, Margins Weak
Zacks Equity Research - Zacks Investment Research - Thu May 05, 8:03AM CDT
Genomic Health (GHDX) started 2016 on a satisfactory note.
BSX: 22.97 (+0.31), SRDX: 24.06 (+0.71), BAX: 45.96 (+1.02), GHDX: 26.59 (+0.11)
Genomic Health Reports Double-Digit Revenue and Test Growth in Announcement of First Quarter 2016 Financial Results
PR Newswire - Wed May 04, 3:05PM CDT
Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended March 31, 2016.
GHDX: 26.59 (+0.11)
Genomic Health to Present at Bank of America Merrill Lynch 2016 Health Care Conference
PR Newswire - Tue May 03, 3:05PM CDT
Genomic Health, Inc. (Nasdaq: GHDX) today announced that Kim Popovits, Chairman of the Board, Chief Executive Officer and President, will present at the Bank of America Merrill Lynch 2016 Health Care Conference at the Encore at Wynn Las Vegas on Tuesday, May 10, 2016 at 3:40 p.m. Pacific Time.
GHDX: 26.59 (+0.11)
3 Things to Watch as Genomic Health, Inc. Releases Earnings
Brian Orelli, The Motley Fool - Motley Fool - Tue May 03, 2:55PM CDT
As Genomic Health prepares to release earnings on Wednesday after the closing bell, here are three things investors should be watching from the cancer-test maker. 1. Tests performed Revenue is important, but with not all of its tests being...
MYGN: 30.76 (-0.21), GHDX: 26.59 (+0.11)
Genomic Health to Announce First Quarter 2016 Financial Results and Host Conference Call on Wednesday, May 4, 2016
PR Newswire - Wed Apr 27, 7:00AM CDT
Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Wednesday, May 4 at 4:30 p.m. Eastern Time to discuss its first quarter 2016 financial results. The call and webcast will follow the release of the first quarter financial results after market close.
GHDX: 26.59 (+0.11)
How Risky Is Myriad Genetics Stock?
Keith Speights, The Motley Fool - Motley Fool - Tue Apr 12, 7:22AM CDT
Image source: Myriad Genetics. April showers bring myriad flowers. That's not really how the old adage goes, but the changed wording just might be applicable to Myriad Genetics . Shares of the molecular diagnostics testing company took a...
MYGN: 30.76 (-0.21), FMI: 19.43 (+0.01), ILMN: 146.59 (+5.70), GHDX: 26.59 (+0.11)
Genomic Health (GHDX): Moving Average Crossover Alert
Zacks Equity Research - Zacks Investment Research - Fri Apr 01, 5:35AM CDT
Genomic Health Inc. (GHDX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
GHDX: 26.59 (+0.11)
Shares of GHDX Down 22.4% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Mar 24, 1:02PM CDT
SmarTrend identified a Downtrend for Genomic Health (NASDAQ:GHDX) on January 11th, 2016 at $29.54. In approximately 2 months, Genomic Health has returned 22.41% as of today's recent price of $22.92.
GHDX: 26.59 (+0.11)
Genomic Health: Bleak Q4 on Lower Margins, Higher Costs
Zacks Equity Research - Zacks Investment Research - Fri Mar 18, 2:00PM CDT
Genomic Health's (GHDX) fourth-quarter 2015 adjusted loss came in wider than expected, while the top line closely missed the Zacks Consensus Estimate
OFIX: 44.22 (-0.11), GHDX: 26.59 (+0.11), HRC: 52.06 (+0.78), OSUR: 6.81 (+0.04)
Genomic's Oncotype DX Positive in 5-Year Breast Cancer Trial
Zacks Equity Research - Zacks Investment Research - Tue Mar 15, 1:10PM CDT
We believe these 5-year favorable results from the PlanB study will enhance Genomic Health's (GHDX) competitive leverage in the billion dollar global market for breast cancer diagnostics and drug technologies.
OFIX: 44.22 (-0.11), GHDX: 26.59 (+0.11), HRC: 52.06 (+0.78), OSUR: 6.81 (+0.04)
